Literature DB >> 8470522

Middle ear barotrauma associated with hyperbaric oxygenation treatment.

Y Igarashi1, Y Watanabe, K Mizukoshi.   

Abstract

We investigated the signs and symptoms of middle ear barotrauma in 67 patients with hyperbaric oxygenation treatment as well as the influence of predisposing factors. Ear damage was classified into 5 grades on the basis of objective findings at otoscopic examination. The incidence of middle ear barotrauma assessed by objective criteria was 68.7%, and showed little variation with age or primary disease. On the other hand, the incidence assessed by subjective symptoms was lower than the objectively-based incidence in aged patients, those with severe neurological diseases, and those who had difficulties speaking. Patients with a trauma grade of 2 or more complained of severe symptoms and were appropriate candidates for treatment. It is considered that otoscopic examination should be performed in patients who undergo hyperbaric oxygenation treatment and that prior management of nasal and paranasal diseases is beneficial in the prevention and treatment of middle ear barotrauma.

Entities:  

Mesh:

Year:  1993        PMID: 8470522     DOI: 10.3109/00016489309128142

Source DB:  PubMed          Journal:  Acta Otolaryngol Suppl        ISSN: 0365-5237


  3 in total

1.  Otological complications associated with hyperbaric oxygen therapy.

Authors:  Yoko Yamamoto; Yoshihiro Noguchi; Mitsuhiro Enomoto; Kazuyoshi Yagishita; Ken Kitamura
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-12-09       Impact factor: 2.503

2.  Effect of antiplatelet and/or anticoagulation medication on the risk of tympanic barotrauma in hyperbaric oxygen treatment patients, and development of a predictive model.

Authors:  Adam E Howard; Peter Buzzacott; Ian C Gawthrope; Neil D Banham
Journal:  Diving Hyperb Med       Date:  2020-12-20       Impact factor: 0.887

3.  MRI findings of otic and sinus barotrauma in patients with carbon monoxide poisoning during hyperbaric oxygen therapy.

Authors:  Ping Wang; Xiao-Ming Zhang; Zhao-Hua Zhai; Pei-Ling Li
Journal:  PLoS One       Date:  2013-06-12       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.